On-Demand Webinar | De-risking biosimilar programs: Tackling biosimilarity challenges
Regulatory focus on interchangeability is making early alignment of protein quality attributes with the originator's profile more critical than ever. This webinar explores how a highly efficient, data-driven approach to cell line development can help you meet these demands without slowing down your timeline.
Using a case study of a biosimilar to a blockbuster biologic, we demonstrate how a comprehensive cell line development approach combines automated clone screening, advanced data modeling, and an early focus on critical quality attributes (CQAs). See how simultaneous process and media optimization, guided by a design of experiments (DoE) approach, helped increase titer and optimize the N-glycan profile — and how several rounds of fine-tuning helped identify a lead clone and ensure a process ready for scale-up.
What You Will Learn:
- Learn how advanced clone screening and DoE can accelerate biosimilar cell line development.
- Discover strategies for controlling CQAS to support regulatory comparability.
- Explore a real-world case study for de-risking development toward commercialization.